Diamyd Medical AB (publ) EBIT

Diamyd Medical AB (publ) (DMYD-B.ST) currently reports a EBIT of $-260M as of August 2026. That compares with $-170M in the prior-year period — down 54.9% year over year. That is below the Healthcare sector average of $130B. Use the charts on this page to explore Diamyd Medical AB (publ)'s EBIT history and peer comparisons.

Diamyd Medical AB (publ)'s EBIT decreased from $-170M to $-260M — a 54.9% year-over-year decrease (period ending August 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Diamyd Medical AB (publ)'s EBIT of $-260M is lower than the Healthcare sector average of $130B. That is roughly 100.2% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Diamyd Medical AB (publ) reported $-260M in EBIT as of August 2026. That compares with $-170M in the prior-year period — down 54.9% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-260M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $130B. From there, open related valuation or income-statement pages for Diamyd Medical AB (publ), and consider following DMYD-B.ST for alerts when major investors trade the stock.